All In Biotech

Drug Trial Radar · NCT06079983

JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Trial Of JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

Last checked: Nov 20, 2026Latest source record: Sep 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 400 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

400

Planned (sponsor's estimate)

Start

Dec 1, 2023

Primary completion

Apr 1, 2026

Study completion Mar 1, 2029

Sponsor

Sponsor type
Industry
First posted
Oct 12, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a randomized controlled, open-label, multicenter phase III clinical study evaluating the efficacy and safety of chemotherapy selected by investigator JSKN003 s in subjects with recurrent or metastatic breast cancer who have previously failed first- or second-line chemotherapy in subjects with recurrent or metastatic breast cancer who have failed prior first- or second-line chemotherapy. The study planned to enroll 408 subjects in a 1:1 ratio and stratified block randomization method assigned to: * Experimental group: JSKN003 monotherapy * Control group: investigator's chosen chemotherapy drug (capecitabine, gemcitabine, vinorelbine, docetaxel, albumin-bound paclitaxel, or eribulin) monotherapy

Conditions

  • Breast Cancer

Interventions

  • JSKN003Drug

    Administered intravenously according to protocol.

  • Capecitabine tabletsDrug

    Administered according to protocol, as one option for investigator's choice (determined before randomization).

  • Gemcitabine hydrochloride for injectionDrug

    Administered according to protocol, as one option for investigator's choice (determined before randomization).

  • Vinorelbine tartrate injectionDrug

    Administered according to protocol, as one option for investigator's choice (determined before randomization).

  • Paclitaxel for injection (albumin-bound type)Drug

    Administered according to protocol, as one option for investigator's choice (determined before randomization).

  • Docetaxel injectionDrug

    Administered according to protocol, as one option for investigator's choice (determined before randomization).

  • Eribulin mesylate injectionDrug

    Administered according to protocol, as one option for investigator's choice (determined before randomization).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS)Time frame: up to approximately 3 years after the first enrollment

Locations

87 sites in 1 country. Site status is shown where the registry gives one.

  • Anyang Cancer Hospital

    Anyang, China · Not yet recruiting

  • Affiliated Hospital of Hebei University

    Baoding, China · Not yet recruiting

  • Beijing Luhe Hospital

    Beijing, China · Not yet recruiting

  • Cancer Hospital, Chinese Academy of Medical Sciences

    Beijing, China · Recruiting

  • Peking University Cancer Hospital

    Beijing, China · Recruiting

  • The First Affiliated Hospital of China Medical University

    Beijing, China · Recruiting

  • The First Medical Center of the General Hospital of the People's Liberation Army Chinese People's Liberation Army

    Beijing, China · Not yet recruiting

  • Bethune First Hospital of Jilin University

    Changchun, China · Not yet recruiting

  • Jilin Provincial Cancer Hospital

    Changchun, China · Not yet recruiting

  • The First People's Hospital of Changde

    Changde, China · Recruiting

  • Central South University Xiangya Hospital

    Changsha, China · Not yet recruiting

  • Hunan Cancer Hospital

    Changsha, China · Recruiting

  • Affiliated Hospital of Chengde Medical University

    Chengde, China · Recruiting

  • Sichuan Cancer Hospital

    Chengdu, China · Recruiting

  • Sichuan Provincial People's Hospital

    Chengdu, China · Recruiting

  • West China Hospital, Sichuan University

    Chengdu, China · Not yet recruiting

  • Cancer Hospital of Chongqing University

    Chongqing, China · Not yet recruiting

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, China · Not yet recruiting

  • The Second Affiliated Hospital of Dalian Medical University

    Dalian, China · Not yet recruiting

  • Fujian Cancer Hospital

    Fuzhou, China · Not yet recruiting

  • Fujian Provincial Hospital

    Fuzhou, China · Recruiting

  • Union Hospital Affiliated to Fujian Medical University

    Fuzhou, China · Recruiting

  • The First Affiliated Hospital of Gannan Medical University

    Ganzhou, China · Recruiting

  • Guangdong Provincial People's Hospital

    Guangzhou, China · Not yet recruiting

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    Guangzhou, China · Not yet recruiting

  • The Affiliated Hospital of Guangdong Medical University

    Guangzhou, China · Recruiting

  • Sun Yat-sen University Cancer Center

    Guanzhou, China · Not yet recruiting

  • Guizhou Provincial People's Hospital

    Guiyang, China · Recruiting

  • The Affiliated Hospital of Guizhou Medical University

    Guiyang, China · Recruiting

  • Harbin Medical University Cancer Hospital

    Ha’erbin, China · Not yet recruiting

  • Run Run Shaw Hospital affiliated to Zhejiang University School of Medicine

    Hangzhou, China · Not yet recruiting

  • The First Affiliated Hospital of Zhejiang University School of Medicine

    Hanzhou, China · Not yet recruiting

  • The Second Affiliated Hospital of Zhejiang University School of Medicine

    Hanzhou, China · Not yet recruiting

  • Zhejiang Cancer Hospital

    Hanzhou, China · Not yet recruiting

  • Anhui Provincial Hospital

    Hefei, China · Not yet recruiting

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, China · Not yet recruiting

  • The Second Affiliated Hospital of Anhui Medical University

    Hefei, China · Not yet recruiting

  • The First Affiliated Hospital of University of South China

    Hengyang, China · Recruiting

  • Affiliated Hospital of Inner Mongolia Medical University

    Hohhot, China · Recruiting

  • Jiangmen Central Hospital

    Jiangmen, China · Recruiting

Showing 40 of 87 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.